Candesartan

An angiotensin receptor blocker blood pressure medicine, FDA-approved for hypertension in adults and children and for heart failure with reduced ejection fraction.

psilodex.org/m/candesartan · data v2026.10.05

Clinical contraindication: None listed; No label contraindication covering psilocybin was found. This is not a finding that the combination has been shown to be without risk.
Psilocybin evidence: No psilocybin data
Half-life: ~9 h; Approximate, in adults. Source under Interaction below.

Named in state rules?

Not namedColorado Condition rules (3)

Not namedOregon

PendingNew Mexico

Cite asPsilodex, “Candesartan”, v2026.10.05. psilodex.org/m/candesartan

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

What it is used for

FDA status

FDA-approved

FDA-approved for

High blood pressure (hypertension), adults and children 1 to <17 years
Heart failure (NYHA class II–IV, ejection fraction ≤40%)

Sources [1]

Other safety

Boxed warning: drugs acting on the renin-angiotensin system can cause injury and death to the developing fetus.

About the medication itself, separate from any interaction with psilocybin.

Sources [1]

01 Interaction with psilocybin

It lowers blood pressure and may lessen psilocybin's brief blood pressure rise (not studied with psilocybin).

Detail Candesartan, an angiotensin receptor blocker, lowers blood pressure and may lessen psilocybin's brief blood pressure rise; this has not been studied with psilocybin. It is not known to affect psilocin's clearance.

Human data with psilocybin: No psilocybin data; based on how it works
Half-life: ~9 h (FDA label, checked 2026-10-04)

Evidence types on this record

No psilocybin dataNo psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts

02 Pharmacology relevant to psilocybin

2 listed · counted on reports

Lowers blood pressure or causes orthostasis: Lowers blood pressure, or causes a drop on standing (orthostasis) that can bring dizziness or fainting. Sources [1]
Dehydration or electrolyte risk: Can cause dehydration or shifts in sodium or potassium. Sources [1]

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Not namedCondition rules (3)

No provision names this medication or its class.

Colorado · checked 2026-10-04

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-10-04

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-04

04 Conditions to ask about

Screening items in state rules

This medication is usually taken for a condition. State rules screen for some conditions directly, so the medication is a prompt to ask about them. Confirm with the participant; never assume a condition from the medication.

Hypertension (provision applies if uncontrolled)
- CO 2.5(A)(2) · Clinical Facilitator licensees
- CO 6.16(F)(2)(a) · Facilitators without a clinical facilitator license
- CO 6.16(F)(1) · All licensees
Heart failure or past heart attack
- CO 2.5(A)(2) · Clinical Facilitator licensees
- CO 6.16(F)(2)(a) · Facilitators without a clinical facilitator license
- CO 6.16(F)(1) · All licensees

05 Sources

ATACAND (candesartan cilexetil) tablets · FDA label (DailyMed) — Lowers blood pressure or causes orthostasis: 5.3 Hypotension "ATACAND can cause symptomatic hypotension." | 12.3 Pharmacokinetics "The elimination half-life of candesartan is approximately 9 hours." | Boxed Warning "Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus" | revised 2025-12 | Warnings and Precautions: Hyperkalemia: "Drugs that inhibit the renin-angiotensin system can cause hyperkalemia."

Record history

v2026.10.02First published.
2026-10-04Last reviewed against its sources.

Report an error in this record →